The emerging role of intravesical botulinum toxin therapy in idiopathic detrusor overactivity

International Journal of Clinical Practice

Volumn 60, Issue SUPPL. 151, 2006, Pages 27-32

  Patel, A K ^a   Patterson, J M ^a   Chapple, Christopher R ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Botox ; Botulinum toxin; Detrusor instability; Idiopathic detrusor overactivity; Overactive bladder syndrome; Urgency incontinence

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CHOLINERGIC RECEPTOR BLOCKING AGENT; LIDOCAINE; PLACEBO;

BLADDER AND BOWEL MANAGEMENT; BLADDER CATHETERIZATION; BLADDER FUNCTION; BLADDER RECONSTRUCTION; CHILDHOOD DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DETRUSOR DYSSYNERGIA; DOSE CALCULATION; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INDICATION; DRUG INJECTION VOLUME; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSURIA; ELDERLY CARE; EVIDENCE BASED MEDICINE; HEMATURIA; HUMAN; INJECTION SITE; INJECTION SITE BURNING; LOW DRUG DOSE; MALAISE; MEDLINE; NEUROMODULATION; OFF LABEL DRUG USE; OVERACTIVE BLADDER; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; REVIEW; SELF MEDICATION; SYSTEMIC DISEASE; UNSPECIFIED SIDE EFFECT; URINARY TRACT DISEASE; URINARY TRACT INFECTION; URINE INCONTINENCE; URINE RETENTION; URODYNAMICS; VESICOURETERAL REFLUX; XEROSTOMIA;

EID: 33751310599     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01212.x     Document Type: Review

References (39)

1. Milsom I, Abrams P, Cardozo L et.al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-6.
2. Milsom I, Stewart W, Thuroff J. The prevalence of overactive bladder. Am J Manag Care 2000; 6 (Suppl. 11): S565-73.
3. Abrams P, Cardozo L, Fall M et.al. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78.
4. Khullar V, Chapple C, Gabriel Z et.al. The effects of antimuscarinics on health-related quality of life in overactive bladder: A systematic review and meta-analysis. Urology 2006; 68 (Suppl. 2): 38-48.
5. Miller J, Hoffman E. The causes and consequences of overactive bladder. J Womens Health (Larchmt) 2006; 15: 251-60.
6. Dmochowski RR. The puzzle of overactive bladder: Controversies, inconsistencies, and insights. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17: 650-8.
7. Dykstra DD, Sidi AA, Scott AB et.al. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988; 139: 919-22.
8. Schurch B, Schmid DM, Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 2000; 2: 665.
9. Schurch B, Stohrer M, Kramer G et.al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results. J Urol 2000; 164 (3 Pt 1): 692-7.
10. Schmid D, John H, Hauri D et.al. Experience of 100 cases treated with botulinum-A toxin injections into the detrusor muscle for overactive bladder refractory to anticholinergics. Eur Urol Suppl 2005; 4: 142 (Abstract 559).
11. Schmid DM, Schurch B, John H et.al. Botulinum toxin injections to treat overactive bladder. Eur Urol Suppl 2004; 3: 131 (Abstract 516).
12. Zermann DH, Ishigooka M, Schmidt RA. Trigonum and bladder base injection of botulinum toxin A (BoNT) in patients with severe urgency-frequency syndrome refractory to conservative medical treatment and electrical stimulation. Neurourol Urodyn 2001; 20: 412-3 (Abstract 27).
13. Sahai A, Khan M, Smith K et.al. Botulinum toxin-A for patients with idiopathic detrusor overactivity: Early results from a randomised, double-blind, placebo-controlled trial. International Continence Society Annual Meeting, 2005 (Abstract 428).
14. Gousse A, Tunuguntla HSGR, Rodriguez D et.al. Dose-Finding Prospective Randomized Study to evaluate the efficacy and safety of botulinum-A toxin for refractory idiopathic overactive bladder. International Continence Society Annual Meeting, 2005 (Abstract 254).
15. Flynn MK, Webster GD, Amundsen CL. The effect of botulinum-A toxin on patients with severe urge urinary incontinence. J Urol 2004; 172 (6 Pt 1): 2316-20.
16. Radziszewski P, Borkowski A. Botulinum toxin type A intravesical injections for intractable bladder overactivity. Eur Urol Suppl 2002; 1: 134.
17. Fowler C, Popat R, Apostolidis A et.al. Intradetrusor injections of botulinum A toxin to treat severe detrusor overactivity. J Neurol Neurosurg Psychiatry 2004; 75: 1216 (Abstract 18).
18. Harper M, Popat RB, Dasgupta R et.al. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 2003; 92: 325-6.
19. Patel AK, Patterson JM, Chapple CR. Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: A critical analysis of results. Eur Urol 2006; 50: 684-710.
20. Abdelmalak JB, Rackley RR, Vasavada SP et.al. Botulinum A toxin (Botox) injection for the treatment of refractory overactive bladder. American Urological Association Annual Meeting, 2004 (Abstract 531).
21. Rajkumar GN, Small DR, Mustafa AW et.al. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 2005; 96: 848-52.
22. Schulte-Baukloh H, Weiss C, Stolze T et.al. Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur Urol 2005; 48: 984-90.
23. Chancellor MB, O'Leary M, Erickson J et.al. Successful use of bladder botulinum toxin injection to treat refractory overactive bladder. J Urol 2003; 169 (Suppl. 4): 351 (Abstract DP50).
24. Schulte-Baukloh H, Weiss C, Stolze T et.al. Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology 2005; 66: 82-7.
25. Kessler TM, Danuser H, Schumacher M et.al. Botulinum A toxin injections into the detrusor: An effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn 2005; 24: 231-6.
26. Werner M, Schmid DM, Schussler B. Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: A prospective nonrandomized study. Am J Obstet Gynecol 2005; 192: 1735-40.
27. Sweeney D, O'Leary M, Erickson J et.al. Safety and efficacy with bladder botulinum toxin in elderly patients. International Continence Society Annual Meeting, 2005 (Abstract 453).
28. Hoebeke P, Decaestecker K, Verleyen P et al. Extended experience with the use of botulinum toxin A in children with non neurogenic voiding dysfunction. ESPU-AAP Joint Conference, 15-18 June 2005, Uppsala, Sweden, 2005 (Abstract 109).
29. Verleyen P, Hoebeke P, Raes A et.al. The use of botulinum toxin A in children with a non-neurogenic overactive bladder: A pilot study. BJU Int 2004; 93 (Suppl. 2): Abstract 138.
30. Peeren F, Everaert K, Hoebeke P et.al. Successive injections of botulinum A toxin (Botox) in paediatric population. International Continence Society Annual Meeting, 2005 (Abstract 270).
31. Hirst G, Wareham K, Emery S et.al. Failure of botulinum toxin type B in the treatment of the refractory overactive bladder. International Continence Society Annual Meeting, 2005 (Abstract 432).
32. Ghei M, Maraj BH, Miller R et.al. Effects of botulinum toxin B on refractory detrusor overactivity: A Randomized, Double-Blind, Placebo Controlled, Crossover Trial. J Urol 2005; 174: 1873-7.
33. Dykstra D, Enriquez A, Valley M. Treatment of overactive bladder with botulinum toxin type B: A pilot study. Int Urogynecol J Pelvic Floor Dysfunct 2003; 14: 424-6.
34. Kalsi V, Popat R, Odyemi I et.al. A cost effectiveness model for botulinum neurotoxin type A (BoNT/A) in the treatment of patients with detrusor overactivity: Preliminary results. British Association of Urological Surgeons Annual Meeting, 2005 (Abstract 61).
35. Popat R, Apostolidis A, Kalsi V et.al. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005; 174: 984-9.
36. Rapp DE, Lucioni A, Katz EE et.al. Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: An initial experience. Urology 2004; 63: 1071-5.
37. Keppenne V, Gaspard Y, Mathantu B et.al. Detrusor injection of botulinum A toxin for idiopathic overactive bladder syndrome: Clinical and urodynamic evaluation. International Continence Society Annual Meeting, 2005 (Abstract 498).
38. Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006; 49: 644-50.
39. Kuo HC. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology 2005; 66: 94-8.